Pathophysiology and management of anemia in chronic progressive renal failure.
Hypoproliferative anemia is a predictable and serious complication of progressive renal failure and contributes significantly to the overall morbidity of the uremic state. Until recently, there has been no satisfactory therapy to resolve the anemia. Now the anemia can be explicitly corrected with erythropoietin-replacement therapy, and the clinical debility generally attributable to renal insufficiency can be lessened and retarded. Anemia must no longer be regarded as an intractable consequence of the uremic syndrome and should be managed as conscientiously as the other polysystemic features of uremia.
Cowgill
L D
LD
Department of Medicine, School of Veterinary Medicine, University of California, Davis 95616.
D000740:Anemia / Q000209:etiology / Q000628:therapy / Q000662:veterinary*; D000818:Animals; D002415:Cats; D004283:Dog Diseases / Q000209:etiology / Q000628:therapy*; D004285:Dogs; D004921:Erythropoietin / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000662:veterinary*; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin